

1474 South Coast Road, Mobeni, 4052, Durban, RSA. P.O. Box 32003, Mobeni, 4060, Durban, RSA.

Tel: +27 (0) 31 451 3800 Fax: +27 (0) 31 451 3889

E-mail: customercare@ciplaman.co.za

24 February 2014

Amafa aKwaZulu-Natali, PO Box 2685 Pietermaritzburg 3200

Sir/Madam

## RE: APPROVAL OF BUILDING CONSTRUCTION PLANS

CIPLA Medpro Manufacturing (CMM) is our manufacturing facility situated in Mobeni, Durban. It is one of South Africa's largest pharmaceutical manufacturing plants and is one of the first local manufacturers to attain PIC/S accreditation allowing it to provide manufacturing solutions in line with the Medicines Control Council (MCC) & current Good Manufacturing Practice (cGMP).

CMM plays a significant role in contributing to the decrease of HIV infections across the country through efforts in simplifying treatment and reducing the cost of ARV treatment. We, as CMM, in partnership with government and healthcare professionals, remain committed to increasing awareness and offering affordable treatment in the fight against HIV/AIDS.

The facility was awarded a significant portion of the antiretroviral (*ARV*) tender from government for the period commencing 1 January 2013 until 31 December 2014.

In our drive to continuously make affordable ARV treatment a reality for all South Africans, we have focused our attention and capital investments towards the field of Fixed Dose Combinations (FDCs), in particular the local manufacturing of a pharmaceutical ARV product called Odimune in our Durban factory. This is single tablet that is designed to deliver 3 ARV's at once to a patient, rather than taking 3 separate tablets. This new regime apart from being cost effective for the National Department of Health will also improve patient compliance and will meet Minister of Health's vision to have affordable health care for all South Africans.

In our effort to achieve our objectives of delivering this vital ARV, we plan to continuously invest in Durban factory to improve efficiencies, create capacity and improve its capabilities. We trust that you will recognize our commitment towards "making it better" for people currently on ARV treatment, and will approve the necessary building construction plans currently in circulation at your offices.

Yours faithfully

Suvrun Rajh General Manager

Ridhan Singh Financial Director

